Ignite Creation Date:
2024-05-06 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05293002
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-05-09
First Post:
2022-01-19
Brief Title:
Belgian Study to Assess the Efficacy and Safety of the RESTORER Iliac Stent for Treatment of Aorto-iliac Lesions
Sponsor:
ID3 Medical
Organization:
ID3 Medical
Study Overview
Official Title:
Belgian Study to Assess the Efficacy and Safety of the RESTORER Iliac Stent System for the Treatment of Aorto-iliac Lesions TASC A B C and D
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BARISTA
Brief Summary:
The BARISTA study tests the safety and efficacy of the Restorer stent from the company iVascular This stent is a medical device that is already approved for use in Europe to treat stenotic narrowed iliac arteries 200 Belgian patients from 13 different hospitals will be included in this study Patients will be medically monitored for 2 years from the day of the study procedure The treatment of the stenotic iliac arteries will be according to the standard of care using the Restorer stent This endovascular treatment consists of introducing the necessary materials in the blood vessels by a puncture in the groin under general or local anaesthesia after which a thin plastic tube will be inserted into the femoral artery through the puncture site until the stenotic iliac artery is reached Medical imaging is done by angiography The stenoticoccluded section of the artery will first be dilated by inserting and inflating a balloon Next the Restorer stent will be placed and if necessary another balloon may be inserted and inflated to allow the stent to fit nicely to the vessel wall and optimise the result As per standard of care follow-up will be done in the hospital after 1 6 12 and 24 months During these visits an ultrasound scan of the treated artery will be taken to evaluate the patency of the blood vessel Also two short questionnaires will be completed asking about the quality of life and walking difficulties The use of medication will be recorded If adverse events are experienced they will be reported
Detailed Description:
Prospective single-arm multicentre physician-initiated clinical study to assess the long-term up to 24 months safety and efficacy of the RESTORER peripheral stent system iVascular for the treatment of iliac lesions in 200 subjects in a controlled clinical setting post CE-certification when used according to the IFU with focus on the treatment of complex TASC A B C and D Aorto-iliac lesions The primary endpoint of the study is freedom of any TLR major amputation or restenosis defined as significant stenosis on duplex ultrasound 50 systolic velocity ratio greater than 24 within 12 months Secondary endpoints are technical success during procedure and during the follow-up period primary patency stent graft occlusion rate ABI freedom from target lesion revascularization clinical success improvement of Rutherford classification change in walking impairment questionnaire change in quality of life questionnaire freedom from above-the-ankle target limb amputation and mortality A subanalysis will be done to compare the results using the TASC classification lesion location AIE AIC bilateral kissing configuration gender diabetes mellitus and Rutherford in terms of patency frequency of TLR and clinical outcome at 12 and 24 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None